epristeride

Known as: 17-N-t-butylcarboxamide androst-3,5-diene-3-carboxylic acid 
 

Topic mentions per year

Topic mentions per year

1993-2017
02419932017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Finasteride and epristeride both inhibit 5α-reductase with high potency via competitive and non-competitive mechanism… (More)
Is this relevant?
2007
2007
A new spectrofluorimetric method to determine epristeride (EP) has been developed, which based on the EP has a strong ability to… (More)
  • figure 1
  • figure 5
  • table 1
  • table 2
  • table 3
Is this relevant?
2002
2002
OBJECTIVES To estimate the clinical safety, efficacy of Epristeride in the treatment of benign prostatic hyperplasia (BPH… (More)
Is this relevant?
2001
2001
The development of benign prostatic hyperplasia (BPH) is an androgen-dependent process that may be mediated by a number of… (More)
Is this relevant?
2001
2001
AIM To study the molecular mechanism of rat prostate atrophy induced by epristeride. METHODS MTT test was used to determine the… (More)
Is this relevant?
1998
1998
  • S S Hedge
  • IDrugs : the investigational drugs journal
  • 1998
Epristeride is a transition-state, noncompetitive steroid 5-alpha-reductase inhibitor under development by SmithKline Beecham for… (More)
Is this relevant?
1998
1998
AIM To evaluate the genetic effects of epristeride (Epr), a new prospective drug for treating benign prostatic hyperplasia… (More)
Is this relevant?
1996
1996
The objective of the current investigation was to describe the pharmacokinetics and absolute oral bioavailability of epristeride… (More)
Is this relevant?
1994
1994
Specificity of an enzyme inhibitor can have profound implications upon the compound's therapeutic potential, utility and safety… (More)
Is this relevant?
1993
1993
An highly sensitive and selective high-performance liquid chromatographic method was developed for the determination of… (More)
Is this relevant?